Sarcoma / 2015 / Article / Fig 1

Research Article

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Figure 1

CONSORT diagram. Patients who received gemcitabine + docetaxel (GD) and placebo were excluded from the toxicity and efficacy analysis of GD + bevacizumab.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.